GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Microbot Medical Inc (NAS:MBOT) » Definitions » ROE %

Microbot Medical (Microbot Medical) ROE % : -212.77% (As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Microbot Medical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Microbot Medical's annualized net income for the quarter that ended in Dec. 2023 was $-12.62 Mil. Microbot Medical's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $5.93 Mil. Therefore, Microbot Medical's annualized ROE % for the quarter that ended in Dec. 2023 was -212.77%.

The historical rank and industry rank for Microbot Medical's ROE % or its related term are showing as below:

MBOT' s ROE % Range Over the Past 10 Years
Min: -1184.19   Med: -125.05   Max: -31.72
Current: -160.47

During the past 13 years, Microbot Medical's highest ROE % was -31.72%. The lowest was -1,184.19%. And the median was -125.05%.

MBOT's ROE % is ranked worse than
91.94% of 806 companies
in the Medical Devices & Instruments industry
Industry Median: 0.15 vs MBOT: -160.47

Microbot Medical ROE % Historical Data

The historical data trend for Microbot Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbot Medical ROE % Chart

Microbot Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -44.09 -32.84 -58.48 -121.53 -182.19

Microbot Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -187.05 -188.05 -127.80 -116.30 -212.77

Competitive Comparison of Microbot Medical's ROE %

For the Medical Instruments & Supplies subindustry, Microbot Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microbot Medical's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's ROE % distribution charts can be found below:

* The bar in red indicates where Microbot Medical's ROE % falls into.



Microbot Medical ROE % Calculation

Microbot Medical's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-10.74/( (7.289+4.501)/ 2 )
=-10.74/5.895
=-182.19 %

Microbot Medical's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-12.616/( (7.358+4.501)/ 2 )
=-12.616/5.9295
=-212.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Microbot Medical  (NAS:MBOT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-12.616/5.9295
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-12.616 / 0)*(0 / 8.6075)*(8.6075 / 5.9295)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.4516
=ROA %*Equity Multiplier
=N/A %*1.4516
=-212.77 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-12.616/5.9295
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-12.616 / -12.616) * (-12.616 / -9.396) * (-9.396 / 0) * (0 / 8.6075) * (8.6075 / 5.9295)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.3427 * N/A % * 0 * 1.4516
=-212.77 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Microbot Medical ROE % Related Terms

Thank you for viewing the detailed overview of Microbot Medical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbot Medical (Microbot Medical) Business Description

Traded in Other Exchanges
Address
25 Recreation Park Drive, Unit 108, Hingham, MA, USA, 02043
Microbot Medical Inc is a pre-clinical medical device company. It specializes in developing next-generation micro-robotic medical technologies that can change the future of medicine. Their vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures and offer physicians and their patients less invasive and more precise solutions. The company's innovative platforms LIBERTY and Self-Cleaning Shunt (SCS) are in one of the fastest-growing segments in healthcare. The group continuously develops its technology with the goal to improve surgical outcomes worldwide. The firm presently holds domestic and global patents that strengthen its product portfolio and create barriers of entry.
Executives
Rachel Vaknin officer: Chief Financial Officer DROR 3/10, ZICHRON YAAKOV L3 3090216
Simon Sharon officer: General Manager & CTO 8 HAMADA STREET, ZICHRON YAACOV L3 3090708
Yoseph Bornstein director, 10 percent owner 16 IRUS STREET, ROSH HA'AYIN L3 4858022
Tal Baruch Wenderow director 1149, BEACON STREET, NEWTON MA 02461
Eyal Morag officer: Chief Medical Officer BONEY HAEAR 3 STREET, APT #13, TEL AVIV L3 6937303
Aileen Ptucha Stockburger director 26 WELLINGTON CT, BELLE MEADE NJ 08502
Harel Gadot director, 10 percent owner, officer: Chairman and CEO 5 VILLAGE LANE, HINGHAM MA 02043
Joseph Mona 10 percent owner 808 HAMPTON ST, COLUMBIA SC 29201
Prattipati Laxminarain director 3 HEWINS FARM ROAD, WELLESLEY MA 02481
Yoav Zvi Waizer director 8 HAVERED STREET, RAANANA L3 4352308
Moshe Shoham director 22 BEDOLACH STREET, HOSHAYA L3 1791500
Leon Lewkowicz 10 percent owner GORDON STREET 10, APARTMENT 7, TEL-AVIV L3 63458
Martin J. Madden director C/O MICROBOT MEDICAL INC., 175 DERBY STREET 27/1, HINGHAM MA 02043
Yehezkel Himelfarb officer: General Manager & COO 32 BEN YOSEF STREET, TEL-AVIV L3 6912530
Sandra Berkson 10 percent owner C/O SABER HOLDING GMBH, WEIN KRUMMBAUMGASSE C4 1020

Microbot Medical (Microbot Medical) Headlines

From GuruFocus

Microbot Medical Expand IP protection in Japan

By Marketwired 06-22-2023